Management of Children Aged Less Than 3 Years With Brain Tumors
- Determine the response rate in children under 36 months of age with primary brain or
brain stem tumors treated with vincristine, methotrexate, carboplatin,
cyclophosphamide, and cisplatin with or without radiotherapy.
- Determine the event-free survival and overall survival in children treated with this
- Determine the pattern of local recurrence or occurrence of CNS metastases in children
treated with this regimen.
- Determine the quality of life in children treated with this regimen.
- Determine the tolerability and long-term toxicity of this regimen in these children.
- Determine the proportion of children who require radiotherapy after treatment with this
- Determine the prognosis of children who receive both chemotherapy and radiotherapy.
- Determine the nature and behavior of brain tumors in very young children.
OUTLINE: This is a multicenter study.
- Chemotherapy: Patients receive vincristine IV on days 0, 14, and 28; carboplatin IV
over 4 hours on day 0; methotrexate IV continuously over 24 hours on day 14;
cyclophosphamide IV over 4 hours on day 28; and cisplatin IV continuously over 48 hours
on days 42 and 43. Courses repeat every 56 days (8 weeks) for up to 12 months. Patients
who achieve a complete response proceed to observation, as do those achieving a partial
response with no tumor present on biopsy. Patients with biopsy proven residual tumors
after 12 months of chemotherapy or recurrent tumors that don't have the potential to
spread through the cerebrospinal fluid (CSF) proceed to local radiotherapy. Patients
with unresponsive disease or progressive disease that has the potential to spread
through the CSF proceed to craniospinal radiotherapy.
- Local radiotherapy: Patients undergo local radiotherapy 5 days a week for 5-5½ weeks.
- Craniospinal radiotherapy: Patients undergo craniospinal radiotherapy 5 days a week for
Quality of life is assessed periodically.
After completion of study treatment, patients are followed periodically for at least 2
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Richard Grundy, MD, PhD
Queen's Medical Centre
United States: Federal Government